368.02

0.00% -0.010

After Hours: 368.02

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $368.02, with a volume of 294.31K. It is down -0.00% in the last 24 hours and up +13.13% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Previous Close:

$368.03

Open:

$374.1

24h Volume:

294.31K

Relative Volume:

0.60

Market Cap:

$10.28B

Revenue:

$7.46M

Net Income/Loss:

$-326.53M

P/E Ratio:

-27.50

EPS:

-13.3803

Net Cash Flow:

$-282.53M

1W Performance:

-0.49%

1M Performance:

+13.13%

6M Performance:

+5.89%

1Y Performance:

+684.02%

1-Day Range:

$361.99

$382.38

1-Week Range:

$360.19

$392.70

52-Week Range:

$37.19

$392.70

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1081)

Industry

Biotechnology (607)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

10,998

Twitter

Next Earnings Date

2026-08-03

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	368.02	10.18B	7.46M	-326.53M	-282.53M	-13.38
VRTX Vertex Pharmaceuticals Inc	552.85	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	833.56	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,019.49	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	158.83	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.38	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-13-26	Initiated	Goldman	Buy
Jun-18-26	Initiated	RBC Capital Mkts	Outperform
Apr-10-26	Initiated	Raymond James	Strong Buy
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-02-26	Initiated	Wells Fargo	Equal Weight
Dec-15-25	Reiterated	Oppenheimer	Outperform
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Aug 21, 2026

PRAX Maintains by Goldman Sachs -- Price Target Raised to $575 - GuruFocus

Aug 21, 2026

Aug 20, 2026

PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits

Aug 20, 2026

Praxis Precision Medicines Slides as Investors Appear to Lock In Gains After Recent Rally - Quiver Quantitative

Aug 20, 2026

Aug 19, 2026

Praxis (PRAX) Update: Climbs 1.92% to $376.94 for the Current Session; the Supplied Trading Band Runs From $358.09 to $395.79Percent Below MA - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Praxis Precision Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits

Aug 18, 2026

Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650 - Moomoo

Aug 18, 2026

Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighWhat's Next? - MarketBeat

Aug 18, 2026

Aug 17, 2026

Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% HigherStill a Buy? - MarketBeat

Aug 17, 2026

Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Nigeria

Aug 17, 2026

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says - marketscreener.com

Aug 17, 2026

Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945 - Moomoo

Aug 17, 2026

Raymond James raises Praxis Precision Medicines price target on pipeline outlook By Investing.com - Investing.com Australia

Aug 17, 2026

Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com Australia

Aug 17, 2026

Aug 16, 2026

Praxis Precision Medicines (PRAX) Holds Near $366.81 as Consolidation Tightens Between Key LevelsBlock Trade Flow - vinanet.vn

Aug 16, 2026

9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB - MarketBeat

Aug 16, 2026

Aug 14, 2026

Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake - Stock Titan

Aug 14, 2026

(PRAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Aug 14, 2026

Aug 13, 2026

Praxis (PRAX) Q2 2026 Earnings Call Transcript - AOL.com

Aug 13, 2026

Aug 12, 2026

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month HighHere's Why - MarketBeat

Aug 12, 2026

Aug 11, 2026

Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportQuality Factor - dars.gov.et

Aug 11, 2026

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView

Aug 11, 2026

Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat

Aug 11, 2026

Aug 10, 2026

H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo

Aug 10, 2026

Weekly Recap: Cash runway into 2028 and RBC raises price target - TradingView

Aug 10, 2026

High Growth Tech Stocks in the US to Watch - simplywall.st

Aug 10, 2026

Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Aug 10, 2026

Aug 09, 2026

Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances - simplywall.st

Aug 09, 2026

Aug 08, 2026

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest? - Yahoo Finance

Aug 08, 2026

LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $754 - Moomoo

Aug 08, 2026

A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,201 - Moomoo

Aug 08, 2026

Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating - marketbeat.com

Aug 08, 2026

A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $462 to $800 - Moomoo

Aug 08, 2026

Aug 07, 2026

JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo

Aug 07, 2026

Praxis: Commercial Launch Could Smash Expectations (Video) - Seeking Alpha

Aug 07, 2026

RBC Adjusts PT on Praxis Precision Medicines to $462 From $449, Keeps Outperform Speculative Risk Rating - Moomoo

Aug 07, 2026

Deutsche Bank Adjusts Praxis Precision Medicines PT to $475 From $374, Maintains Buy Rating - marketscreener.com

Aug 07, 2026

Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 07, 2026